ConductScience.org, home

Paper36923693

A Preclinical Study Comparing the Activity and Potency of OnabotulinumtoxinA and PrabotulinumtoxinA.

Rupp DC and 6 others. Clin Cosmet Investig Dermatol, 2023. Cited by 9 papers, by iCite.

Cite this record

ConductScience Library. A Preclinical Study Comparing the Activity and Potency of OnabotulinumtoxinA and PrabotulinumtoxinA. Papers, record 36923693. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36923693

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A Preclinical Study Comparing the Activity and Potency of OnabotulinumtoxinA and PrabotulinumtoxinA.
PubMed
Journal
Clin Cosmet Investig Dermatol
PubMed
Year
2023
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
9
iCite
Relative citation ratio, by iCite
3.34
iCite
Revised in PubMed
2023-03-16
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Rupp DCDavid C
2Canty DDavid
3Rhéaume CCatherine
4Sondergaard BBirgitte
5Niño CCelina
6Broide RSRon Shttps://orcid.org/0000-0003-1747-0116
7Brideau-Andersen ADAmy D

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References39

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
117097394Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: a double-blind, randomized study.J Am Acad Dermatol2006https://conductscience.org/library/papers/17097394PubMed
233456901Non-inferiority statistics and equivalence studies.BJA Educ2019https://conductscience.org/library/papers/33456901PubMed
321825992Compositional differences among commercially available botulinum toxin type A.Curr Opin Ophthalmol2011https://conductscience.org/library/papers/21825992PubMed
411714400Noninferiority trials.Curr Control Trials Cardiovasc Med2000https://conductscience.org/library/papers/11714400PubMed
523458294
The convergence of medicine and neurotoxins: a focus on botulinum toxin type A and its application in aesthetic medicine--a global, evidence-based botulinum toxin consensus education initiative: part I: botulinum toxin in clinical and cosmetic practice.
Dermatol Surg2013https://conductscience.org/library/papers/23458294PubMed
625059456Blepharospasm: long-term treatment with either Botox®, Xeomin® or Dysport®.J Neural Transm (Vienna)2015https://conductscience.org/library/papers/25059456PubMed
723400888Abo-, inco-, ona-, and rima-botulinum toxins in clinical therapy: a primer.Pharmacotherapy2013https://conductscience.org/library/papers/23400888PubMed
827268041In-vivo comparison of the neurotoxic potencies of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA.Neurosci Lett2016https://conductscience.org/library/papers/27268041PubMed
929633692Pharmacological differences and clinical implications of various botulinum toxin preparations: a critical appraisal.Funct Neurol2018https://conductscience.org/library/papers/29633692PubMed
1025336912Botulinum toxin type A products are not interchangeable: a review of the evidence.Biologics2014https://conductscience.org/library/papers/25336912PubMed
1124587850Comparison and overview of currently available neurotoxins.J Clin Aesthet Dermatol2014https://conductscience.org/library/papers/24587850PubMed
1223868503Diffusion, spread, and migration of botulinum toxin.Mov Disord2013https://conductscience.org/library/papers/23868503PubMed
1330893169Efficacy and Safety of Prabotulinumtoxin A and Onabotulinumtoxin A for Crow's Feet: A Phase 3, Multicenter, Randomized, Double-Blind, Split-Face Study.Dermatol Surg2019https://conductscience.org/library/papers/30893169PubMed
1426509943A Randomized, Double-Blind Trial to Investigate the Equivalence of IncobotulinumtoxinA and OnabotulinumtoxinA for Glabellar Frown Lines.Dermatol Surg2015https://conductscience.org/library/papers/26509943PubMed
1520369902Botulinum toxin: examining duration of effect in facial aesthetic applications.Am J Clin Dermatol2010https://conductscience.org/library/papers/20369902PubMed
1627673516Advancements and Refinement in Facial Neuromodulators.Plast Reconstr Surg2016https://conductscience.org/library/papers/27673516PubMed
1732866999The mechanisms of action and use of botulinum neurotoxin type A in aesthetics: Key Clinical Postulates II.J Cosmet Dermatol2020https://conductscience.org/library/papers/32866999PubMed
1811600142A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice.Toxicon2001https://conductscience.org/library/papers/11600142PubMed
1928356439Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology.Pharmacol Rev2017https://conductscience.org/library/papers/28356439PubMed
2022069680Characterization of SNARE cleavage products generated by formulated botulinum neurotoxin type-a drug products.Toxins (Basel)2010https://conductscience.org/library/papers/22069680PubMed

See all 39 referencesDownload CSV of references

Cited by8

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.

PMIDTitleJournalYearIn PapersSource
42957223Dose-dependent Effects of Botulinum Toxin Type E in the Mouse Digit Abduction Score Model.In Vivo2026https://conductscience.org/library/papers/42957223PubMed
42429953Botulinum Toxin A Myths, Evidence, and Global Media Narratives.Aesthetic Plast Surg2026https://conductscience.org/library/papers/42429953PubMed
41745765Cross-Induction of Anti-Complexing Antibodies in Patients Treated with Botulinum Toxin Formulations Containing Complexing Proteins.Toxins (Basel)2026https://conductscience.org/library/papers/41745765PubMed
41508559Cosmetic Botulinum Toxin A Injections to the Upper Face: A Systematic Review and Meta-Analysis of Clinical Studies.J Cosmet Dermatol2026https://conductscience.org/library/papers/41508559PubMed
41150202RelabotulinumtoxinA, a Ready-to-Use Formulation Neuromodulator Manufactured with PEARL™ Technology to Maintain High Biological and Specific Activity.Toxins (Basel)2025https://conductscience.org/library/papers/41150202PubMed
40593115Decades of Scientific Data and Global Media Reporting on Complications in Non-surgical Aesthetic Treatments for a Transparent Safety Profile: Kissing Snow White Awake.Aesthetic Plast Surg2025https://conductscience.org/library/papers/40593115PubMed
40423313Preclinical Evaluation of Botulinum Toxin Type E (TrenibotulinumtoxinE) Using the Mouse Digit Abduction Score (DAS) Assay.Toxins (Basel)2025https://conductscience.org/library/papers/40423313PubMed
38025648Tailored Indications for Different Neurotoxins.Plast Reconstr Surg Glob Open2023https://conductscience.org/library/papers/38025648PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ALB213PubTator's text mininghttps://conductscience.org/library/genes/213NCBI Gene
SNAP256616PubTator's text mininghttps://conductscience.org/library/genes/6616NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36923693

GET https://conductscience.org/api/papers/v1/36923693/references?page=2